Astrazeneca Pharma India is reportedly planning to close its Avishkar research and development (R&D) site in Bangalore later this year. The decision is part of the company’s broader global business strategy to simplify its research and development footprint and focus resources on three core therapy areas such as oncology, cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity.
The site was working on pharmaceutical development projects and it will no longer carry out early stage research into neglected tropical diseases, TB and malaria.
Astrazeneca Pharma India is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1226.10 |
| Cipla | 1228.55 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2326.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: